We are live on ! Find out more
DRNA

Dicerna Pharmaceuticals, Inc.
DRNA

Delisted

DRNA was delisted on the 27th of December, 2021.

Back to rankings

50 hedge funds and large institutions have $352M invested in Dicerna Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

441% more capital invested

Capital invested by funds: $65.1M → $352M (+$287M)

400% more funds holding in top 10

Funds holding in top 10: 1 → 5 (+4)

233% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 6

167% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 6

35% more funds holding

Funds holding: 37 → 50 (+13)

Holders
50
Holders Change
+13
Holders Change %
+35.14%
% of All Funds
1.13%
Holding in Top 10
5
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+400%
% of All Funds
0.11%
New
20
Increased
16
Reduced
6
Closed
6
Calls
$2.28M
Puts
–
Net Calls
+$2.28M
Net Calls Change
+$2.25M

Top Buyers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
+$28.5M
2
CAM
Cormorant Asset Management
Massachusetts
+$26.9M
3
RI
RTW Investments
New York
+$21.8M
4
RCM
RA Capital Management
Massachusetts
+$18.7M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$14.5M

Top Sellers

Rank Fund Capital Flow
1
EAM
Eventide Asset Management
Massachusetts
-$2.17M
2
6CM
683 Capital Management
New York
-$1.55M
3
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
-$397K
4
BCM
Bourgeon Capital Management
Connecticut
-$190K
5
BCM
Bridgeway Capital Management
Texas
-$135K
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$828K – – –
Millennium Management
27
Millennium Management
New York
$604K +$289K +39,348 +143%
EI
28
EAM Investors
California
$581K +$473K +64,340 New
OAM
29
Oxford Asset Management
United Kingdom
$498K +$391K +53,162 New
BC
30
Birchview Capital
Vermont
$406K – – –
California Public Employees Retirement System
31
California Public Employees Retirement System
California
$370K – – –
Northern Trust
32
Northern Trust
Illinois
$327K +$2K +272 +0.8%
JP Morgan Chase
33
JP Morgan Chase
New York
$320K +$249K +33,823 +2,114%
EA
34
Emerald Advisers
Pennsylvania
$266K +$217K +29,504 New
Barclays
35
Barclays
United Kingdom
$194K +$157K +21,400 +27,436%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$177K -$66.1K -8,985 -31%
ECM
37
Endurant Capital Management
California
$170K +$139K +18,837 New
Dimensional Fund Advisors
38
Dimensional Fund Advisors
Texas
$165K -$66.9K -9,098 -33%
AGM
39
Alpine Global Management
New York
$104K +$84.4K +11,473 New
TRCT
40
Tower Research Capital (TRC)
New York
$95K +$77.7K +10,560 New
State Street
41
State Street
Massachusetts
$94K +$75.9K +10,321 New
PAM
42
Panagora Asset Management
Massachusetts
$68K +$23.7K +3,215 +74%
Morgan Stanley
43
Morgan Stanley
New York
$17K +$5.04K +685 +58%
Royal Bank of Canada
44
Royal Bank of Canada
Ontario, Canada
$9K +$7.41K +1,007 +11,189%
Manulife (Manufacturers Life Insurance)
45
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$7K +$5.93K +806 New
AG
46
Advisor Group
Arizona
$5K +$3.68K +500 New
DCM
47
Delpha Capital Management
New York
$4K +$3.44K +467 New
WAM
48
Wealthspire Advisors (Maryland)
Maryland
$2K – – –
LTFS
49
Ladenburg Thalmann Financial Services
Florida
$1K +$736 +100 New
BNP Paribas Financial Markets
50
BNP Paribas Financial Markets
France
$289 – – –
1
2
3

DRNA Hedge Fund Activity: Q4 2017 in Review

50 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q4 2017, worth a combined $352M — up 441% from $65.1M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new DRNA positions and 6 closed out — a net gain of 14 holders — while 16 added to existing stakes and 6 trimmed.

The largest buyer was EcoR1 Capital, adding an estimated $28.5M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $2.17M sold.

  • 50 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q4 2017, up from 37 in Q3 2017.
  • Funds reported $352M of Dicerna Pharmaceuticals, Inc. stock for Q4 2017, up 441% quarter-over-quarter.
  • 20 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q4 2017 and 6 closed out, a net change of +14 holders.
  • The largest Dicerna Pharmaceuticals, Inc. buyer in Q4 2017 was EcoR1 Capital, an estimated $28.5M added.
  • The largest Dicerna Pharmaceuticals, Inc. seller in Q4 2017 was Eventide Asset Management, an estimated $2.17M sold.

Based on aggregated 13F filings for Q4 2017.